Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors

被引:28
|
作者
Kannan, R
Ruff, M
Kochins, JG
Manly, SP
Stoll, I
El Fahime, M
Noël, A
Foidart, JM
Rio, MC
Dive, V
Basset, P
机构
[1] Univ Strasbourg 1, IGBMC, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
[3] Univ Liege, Lab Biol Tumeurs & Dev, B-4000 Liege, Belgium
[4] CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France
关键词
alpha-1 proteinase inhibitor; cephalosporin; matrix metalloproteinase inhibitors; stromelysin-3;
D O I
10.1006/prep.1999.1068
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The matrix metalloproteinase (MMP) stromelysin-3 (ST3) has been shown to be involved in malignant tumor progression and therefore represents an attractive therapeutical target. In order to screen for ST3 synthetic inhibitors, we have produced and purified the catalytic domain of ST3, matrilysin, stromelysin-a, and membrane type-1 MMP from inclusion bodies in a bacterial system. Our strategy allowed the purification of MMPs directly in the active form, thereby avoiding in vitro activation. A total of 140,000 synthetic compounds from the Bristol-Myers Pharmaceutical Research Institute chemical deck were tested, using a substrate-based colorimetric enzymatic assay, in which ST3 activity was evaluated through its ability to cleave and inactivate alpha-1 proteinase inhibitor. One ST3 inhibitor belonging to the cephalosporin family of antibiotics was thereby identified. (C) 1999 Academic Press.
引用
收藏
页码:76 / 83
页数:8
相关论文
共 50 条
  • [21] Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry
    Parker, MH
    Lunney, EA
    Ortwine, DF
    Pavlovsky, AG
    Humblet, C
    Brouillette, CG
    BIOCHEMISTRY, 1999, 38 (41) : 13592 - 13601
  • [22] Matrix metalloproteinase–inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors
    Luis A. Alcaraz
    Lucia Banci
    Ivano Bertini
    Francesca Cantini
    Antonio Donaire
    Leonardo Gonnelli
    JBIC Journal of Biological Inorganic Chemistry, 2007, 12 : 1197 - 1206
  • [23] The matrix metalloproteinase stromelysin-3 cleaves laminin receptor at two distinct sites between the transmembrane domain and laminin binding sequence within the extracellular domain
    Tosikazu AMANO
    Olivia KWAK
    Liezhen FU
    Anastasia MARSHAK
    Yun-Bo SHI
    Cell Research, 2005, 15 : 150 - 159
  • [24] Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis
    Lohmander, LS
    Brandt, KD
    Mazzuca, SA
    Katz, BP
    Larsson, S
    Struglics, A
    Lane, KA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (10): : 3160 - 3167
  • [25] The matrix metalloproteinase stromelysin-3 cleaves laminin receptor at two distinct sites between the transmembrane domain and laminin binding sequence within the extracellular domain
    Tosikazu AMANO
    Olivia KWAK
    Anastasia MARSHAK
    CellResearch, 2005, (03) : 150 - 159
  • [26] The matrix metalloproteinase stromelysin-3 cleaves laminin receptor at two distinct sites between the transmembrane domain and laminin binding sequence within the extracellular domain
    Amano, T
    Kwak, O
    Fu, LZ
    Marshak, A
    Shi, YB
    CELL RESEARCH, 2005, 15 (03) : 150 - 159
  • [27] Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase
    Luo, DC
    Mari, B
    Stoll, I
    Anglard, P
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) : 25527 - 25536
  • [28] Spatio-temporal regulation and cleavage by matrix metalloproteinase stromelysin-3 implicate a role for laminin receptor in intestinal remodeling during Xenopus laevis metamorphosis
    Amano, T
    Fu, LZ
    Marshak, A
    Kwak, O
    Shi, YB
    DEVELOPMENTAL DYNAMICS, 2005, 234 (01) : 190 - 200
  • [29] Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors
    Alcaraz, Luis A.
    Banci, Lucia
    Bertini, Ivano
    Cantini, Francesca
    Donaire, Antonio
    Gonnelli, Leonardo
    JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2007, 12 (08): : 1197 - 1206
  • [30] EXPRESSION OF STROMELYSIN-3 AND TISSUE INHIBITORS OF MATRIX METALLO-PROTEINASES, TIMP-1 AND TIMP-2, IN RHEUMATOID-ARTHRITIS
    NAWROCKI, B
    POLETTE, M
    CLAVEL, C
    MORRONE, A
    ESCHARD, JP
    ETIENNE, JC
    BIREMBAUT, P
    PATHOLOGY RESEARCH AND PRACTICE, 1994, 190 (07) : 690 - 696